EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a Current Good Manufacturing Practice–Compliant Process for Producing Cryptosporidium parvum Oocysts for Clinical Use

Rajiv S Jumani iD, Bryanna Thomas iD, Jay Lakshman iD, Christian Ostermeier, Natko Nuber, Juergen Hubert Blusch, Sofia Braud-Perez, Dean Wetty, Lizhuo Nouaime, Juergen Dederichs, Joseph Etse, Slobodan Grubesic und 11 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiag107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Rajiv S Jumani und 22 weiteren Autor:innen. Beteiligte Einrichtung: Global Health, Biomedical Research, Novartis, Emeryville, California, USA. Hauptthemen laut MEDLINE: Cryptosporidium parvum, Oocysts, Cryptosporidiosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cryptosporidiosis is a leading cause of severe diarrhea and mortality in young children, with no vaccine or effective treatment. A Cryptosporidium controlled human infection model (CHIM) in healthy adults provides an opportunity to evaluate the safety and efficacy of novel chemical entities prior to testing in young pediatric patients. However, CHIM development has been hindered by the lack of current Good Manufacturing Practice (cGMP)–compliant Cryptosporidium parvum oocysts, which are required for filing an Investigational New Drug (IND) application with the US Food and Drug Administration.

Methods

To overcome this barrier, we developed a cGMP-compliant process for producing C. parvum oocysts. The approach involved sourcing well-characterized oocysts purified from neonatal calves under controlled non-GMP conditions, followed by cGMP processing that included peracetic acid–based surface sanitization, comprehensive microbial testing, and release as a nonsterile oral product for human use.

Results

Peracetic acid (0.5% for 20 minutes) treated C. parvum oocysts demonstrated acceptable microbial safety and preserved viability. Viability was assessed through oocyst excystation, HCT-8 cell infection, and mouse infectivity studies. The cGMP-produced C. parvum oocysts with stringent batch release test criteria for quantity, purity, identity, potency, and bioburden was released as ABO809 for clinical use under an IND. ABO809 was successfully used in human challenge studies, producing reliable infection and characteristic clinical symptoms in healthy adult volunteers.

Conclusions

We describe a robust cGMP-compliant and qualification process for C. parvum oocysts that enables CHIM studies in healthy adults, thereby opening avenues to evaluate efficacy of novel therapeutics and vaccines to treat cryptosporidiosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cryptosporidium parvumOocystsCryptosporidiosisAnimalsHumansMiceCattlePeracetic AcidFemaleDisease Models, AnimalHuman Challenge Trials as Topic

Stichwörter der Autor:innen

controlled human infection modelcryptosporidiosiscurrent good manufacturing practicediarrheaperacetic acid

Substanzen

Peracetic Acid

Autor:innen und Institutionen

  • Global Health, Biomedical Research, Novartis, Emeryville, California, USA.
  • Technical Research and Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Scientific Office DS, Novartis Pharma AG, Basel, Switzerland.
  • Analytical Project Leadership, Science & Technology, Novartis Pharma AG, Basel, Switzerland.
  • Regulatory Affairs, Novartis Pharma AG, Basel, Switzerland.
  • Regulatory Affairs, Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA.

ORCID-Profile: Rajiv S Jumani, Bryanna Thomas, Jay Lakshman, Suresh B Lakshminarayana, Lucy C Watson, Johanne Blais, Deborah A Schaefer, Michael W Riggs, Christopher D Huston, Thierry T Diagana, Ujjini H Manjunatha

Zitieren

APA

Jumani, R. S., Thomas, B., Lakshman, J., Ostermeier, C., Nuber, N., Blusch, J. H., Braud-Perez, S., Wetty, D., Nouaime, L., Dederichs, J., Etse, J., Grubesic, S., Lakshminarayana, S. B., Watson, L. C., Blais, J., Thompson, Z., Jaber, T. Z., Jones, M. R., Schaefer, D. A., …, & Manjunatha, U. H. (2026). Development of a Current Good Manufacturing Practice–Compliant Process for Producing Cryptosporidium parvum Oocysts for Clinical Use. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag107

Vancouver

Jumani RS, Thomas B, Lakshman J, Ostermeier C, Nuber N, Blusch JH, et al. Development of a Current Good Manufacturing Practice–Compliant Process for Producing Cryptosporidium parvum Oocysts for Clinical Use. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag107

BibTeX
@article{Jumani2026,
  author = {Jumani, Rajiv S and Thomas, Bryanna and Lakshman, Jay and Ostermeier, Christian and Nuber, Natko and Blusch, Juergen Hubert and Braud-Perez, Sofia and Wetty, Dean and Nouaime, Lizhuo and Dederichs, Juergen and Etse, Joseph and Grubesic, Slobodan and Lakshminarayana, Suresh B and Watson, Lucy C and Blais, Johanne and Thompson, Zachary and Jaber, Tareq Z and Jones, Mark R and Schaefer, Deborah A and Riggs, Michael W and Huston, Christopher D and Diagana, Thierry T and Manjunatha, Ujjini H},
  title = {Development of a Current Good Manufacturing Practice–Compliant Process for Producing Cryptosporidium parvum Oocysts for Clinical Use},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiag107}
}
Kostenlos starten →